MET and neoplasm: Indeed, rare MET amplified cell subpopulations, representing <1% of cells in a tumor, have reportedly been uncovered in treatment-naïve cases of EGFRm+ NSCLC that subsequently progressed on EGFR-TKIs with MET amplification as the main mechanism of resistance [77,83].